Brief: Phase 1a/1b Study Results of Akeso's PD-1/CTLA-4 Bispecific Antibody Published in Cell Reports Medicine
19/10/2023 14:58
Oct 19 (Reuters) - Akeso Inc 9926.HK :
* PHASE 1A/1B STUDY RESULTS OF AKESO'S PD-1/CTLA-4
BISPECIFIC
ANTIBODY PUBLISHED IN CELL REPORTS MEDICINE, HIGHLIGHTING
PROMISING EFFICACY IN SOLID TUMORS REFRACTORY/RELAPSED TO
STANDARD THERAPY
Source text for Eikon: ID:nPn5T3tvVa
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals